

France MentrÃ©

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5767459/publications.pdf>

Version: 2024-02-01

91
papers

6,618
citations

94433

37
h-index

69250

77
g-index

98
all docs

98
docs citations

98
times ranked

9963
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical and virological data of the first cases of COVID-19 in Europe: a case series. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 697-706.	9.1	953
2	Type 1 interferons as a potential treatment against COVID-19. <i>Antiviral Research</i> , 2020, 178, 104791.	4.1	425
3	Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea. <i>PLoS Medicine</i> , 2016, 13, e1001967.	8.4	382
4	Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: The npde add-on package for R. <i>Computer Methods and Programs in Biomedicine</i> , 2008, 90, 154-166.	4.7	370
5	Metrics for External Model Evaluation with an Application to the Population Pharmacokinetics of Clidazide. <i>Pharmaceutical Research</i> , 2006, 23, 2036-2049.	3.5	268
6	Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017, 6, 87-109.	2.5	261
7	Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 209-221.	9.1	233
8	Modeling SARS-CoV-2 viral kinetics and association with mortality in hospitalized patients from the French COVID cohort. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	181
9	Timing of Antiviral Treatment Initiation is Critical to Reduce SARS-CoV-2 Viral Load. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2020, 9, 509-514.	2.5	170
10	Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005389.	3.0	153
11	Are Population Pharmacokinetic and/or Pharmacodynamic Models Adequately Evaluated?. <i>Clinical Pharmacokinetics</i> , 2007, 46, 221-234.	3.5	149
12	Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action. <i>Clinical Pharmacokinetics</i> , 2010, 49, 17-45.	3.5	140
13	Estimation of Population Pharmacokinetic Parameters of Saquinavir in HIV Patients with the MONOLIX Software. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2007, 34, 229-249.	1.8	135
14	Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials. <i>Clinical Pharmacokinetics</i> , 2016, 55, 907-923.	3.5	135
15	Extension of the SAEM algorithm to left-censored data in nonlinear mixed-effects model: Application to HIV dynamics model. <i>Computational Statistics and Data Analysis</i> , 2006, 51, 1562-1574.	1.2	126
16	Protection of the Human Gut Microbiome From Antibiotics. <i>Journal of Infectious Diseases</i> , 2018, 217, 628-636.	4.0	124
17	Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs. <i>Computer Methods and Programs in Biomedicine</i> , 2001, 65, 141-151.	4.7	122
18	Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques. <i>PLoS Medicine</i> , 2018, 15, e1002535.	8.4	108

#	ARTICLE	IF	CITATIONS
19	Ciprofloxacin Dosage and Emergence of Resistance in Human Commensal Bacteria. <i>Journal of Infectious Diseases</i> , 2009, 200, 390-398.	4.0	105
20	Prediction Discrepancies for the Evaluation of Nonlinear Mixed-Effects Models. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2006, 33, 345-367.	1.8	94
21	Persistent COVID-19 symptoms are highly prevalent 6 months after hospitalization: results from a large prospective cohort. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1041.e1-1041.e4.	6.0	88
22	Further Developments of the Fisher Information Matrix in Nonlinear Mixed Effects Models with Evaluation in Population Pharmacokinetics. <i>Journal of Biopharmaceutical Statistics</i> , 2003, 13, 209-227.	0.8	87
23	Non-Linear Mixed Effects Modeling – From Methodology and Software Development to Driving Implementation in Drug Development Science. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2005, 32, 161-183.	1.8	87
24	Dose regimen of favipiravir for Ebola virus disease. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 150-151.	9.1	86
25	Evaluation of different tests based on observations for external model evaluation of population analyses. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2010, 37, 49-65.	1.8	72
26	Design evaluation and optimisation in multiple response nonlinear mixed effect models: PFIM 3.0. <i>Computer Methods and Programs in Biomedicine</i> , 2010, 98, 55-65.	4.7	68
27	Fisher information matrix for non-linear mixed-effects models: evaluation and application for optimal design of enoxaparin population pharmacokinetics. <i>Statistics in Medicine</i> , 2002, 21, 2623-2639.	1.6	65
28	Methods and software tools for design evaluation in population pharmacokinetics-pharmacodynamics studies. <i>British Journal of Clinical Pharmacology</i> , 2015, 79, 6-17.	2.4	65
29	Favipiravir Pharmacokinetics in Nonhuman Primates and Insights for Future Efficacy Studies of Hemorrhagic Fever Viruses. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	59
30	Ebola virus dynamics in mice treated with favipiravir. <i>Antiviral Research</i> , 2015, 123, 70-77.	4.1	57
31	Design in nonlinear mixed effects models: Optimization using the Fedorov-Wynn algorithm and power of the Wald test for binary covariates. <i>Statistics in Medicine</i> , 2007, 26, 5162-5179.	1.6	55
32	Ebola viral dynamics in nonhuman primates provides insights into virus immuno-pathogenesis and antiviral strategies. <i>Nature Communications</i> , 2018, 9, 4013.	12.8	54
33	Evaluation of bootstrap methods for estimating uncertainty of parameters in nonlinear mixed-effects models: a simulation study in population pharmacokinetics. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2014, 41, 15-33.	1.8	53
34	The use of simulated annealing for finding optimal population designs. <i>Computer Methods and Programs in Biomedicine</i> , 2002, 69, 25-35.	4.7	49
35	Favipiravir for children with Ebola. <i>Lancet</i> , The, 2015, 385, 603-604.	13.7	43
36	Performance Comparison of Various Maximum Likelihood Nonlinear Mixed-Effects Estimation Methods for Dose-Response Models. <i>AAPS Journal</i> , 2012, 14, 420-432.	4.4	42

#	ARTICLE	IF	CITATIONS
37	Ceftriaxone and Cefotaxime Have Similar Effects on the Intestinal Microbiota in Human Volunteers Treated by Standard-Dose Regimens. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	41
38	SARS-CoV-2 viral dynamics in non-human primates. <i>PLoS Computational Biology</i> , 2021, 17, e1008785.	3.2	41
39	Global outbreak research: harmony not hegemony. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 770-772.	9.1	40
40	Maximum Likelihood Estimation of Long-Term HIV Dynamic Models and Antiviral Response. <i>Biometrics</i> , 2011, 67, 250-259.	1.4	39
41	Nonlinear Mixed-Effect Models for Prostate-Specific Antigen Kinetics and Link with Survival in the Context of Metastatic Prostate Cancer: a Comparison by Simulation of Two-Stage and Joint Approaches. <i>AAPS Journal</i> , 2015, 17, 691-699.	4.4	38
42	Impact of Antibiotic Gut Exposure on the Temporal Changes in Microbiome Diversity. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	35
43	Impact on disease mortality of clinical, biological, and virological characteristics at hospital admission and overtime in COVID-19 patients. <i>Journal of Medical Virology</i> , 2021, 93, 2149-2159.	5.0	35
44	Population pharmacokinetics of imipenem in critically ill patients with suspected ventilator-associated pneumonia and evaluation of dosage regimens. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 1022-1034.	2.4	34
45	Dose Rationale for Favipiravir Use in Patients Infected With SARS-CoV-2. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 188-188.	4.7	34
46	Mathematical Modeling of Bacterial Kinetics to Predict the Impact of Antibiotic Colonic Exposure and Treatment Duration on the Amount of Resistant Enterobacteria Excreted. <i>PLoS Computational Biology</i> , 2014, 10, e1003840.	3.2	32
47	Population pharmacokinetic analysis of mizolastine and validation from sparse data on patients using the nonparametric maximum likelihood method. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1998, 26, 133-161.	0.6	28
48	Fisher information matrix for nonlinear mixed effects multiple response models: Evaluation of the appropriateness of the first order linearization using a pharmacokinetic/pharmacodynamic model. <i>Statistics in Medicine</i> , 2009, 28, 1940-1956.	1.6	28
49	Nonlinear joint models for individual dynamic prediction of risk of death using Hamiltonian Monte Carlo: application to metastatic prostate cancer. <i>BMC Medical Research Methodology</i> , 2017, 17, 105.	3.1	28
50	Association Between Tumor Size Kinetics and Survival in Patients With Urothelial Carcinoma Treated With Atezolizumab: Implication for Patient Follow-Up. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 810-820.	4.7	27
51	PFIM 4.0, an extended R program for design evaluation and optimization in nonlinear mixed-effect models. <i>Computer Methods and Programs in Biomedicine</i> , 2018, 156, 217-229.	4.7	25
52	Effect of remdesivir on viral dynamics in COVID-19 hospitalized patients: a modelling analysis of the randomized, controlled, open-label DisCoVeRy trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 1404-1412.	3.0	25
53	Implementation and Evaluation of the SAEM Algorithm for Longitudinal Ordered Categorical Data with an Illustration in Pharmacokinetics-Pharmacodynamics. <i>AAPS Journal</i> , 2011, 13, 44-53.	4.4	24
54	Extension of NPDE for evaluation of nonlinear mixed effect models in presence of data below the quantification limit with applications to HIV dynamic model. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2012, 39, 499-518.	1.8	23

#	ARTICLE	IF	CITATIONS
55	Lessons learned from IDeAl – 33 recommendations from the IDeAl-net about design and analysis of small population clinical trials. <i>Orphanet Journal of Rare Diseases</i> , 2018, 13, 77.	2.7	22
56	Modeling Favipiravir Antiviral Efficacy Against Emerging Viruses: From Animal Studies to Clinical Trials. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2020, 9, 258-271.	2.5	20
57	Impact of imiglucerase on the serum glycosylated-ferritin level in Gaucher disease. <i>Blood Cells, Molecules, and Diseases</i> , 2011, 46, 34-38.	1.4	19
58	Protection of Hamsters from Mortality by Reducing Fecal Moxifloxacin Concentration with DAV131A in a Model of Moxifloxacin-Induced <i>Clostridium difficile</i> Colitis. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	19
59	Design evaluation and optimisation in crossover pharmacokinetic studies analysed by nonlinear mixed effects models. <i>Statistics in Medicine</i> , 2012, 31, 1043-1058.	1.6	18
60	Antibiotic-Induced Dysbiosis Predicts Mortality in an Animal Model of <i>Clostridium difficile</i> Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	18
61	Pharmacometrics and Systems Pharmacology 2030. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 76-78.	4.7	18
62	Once-Daily Dosing of Saquinavir Soft-Gel Capsules and Ritonavir Combination in HIV-1-Infected Patients (Imea015 Study). <i>Antiviral Therapy</i> , 2004, 9, 247-256.	1.0	15
63	Design evaluation and optimization for models of hepatitis C viral dynamics. <i>Statistics in Medicine</i> , 2011, 30, 1045-1056.	1.6	14
64	An MCMC method for the evaluation of the Fisher information matrix for non-linear mixed effect models. <i>Biostatistics</i> , 2016, 17, 737-750.	1.5	13
65	Implementation of a non-human primate model of Ebola disease: Infection of Mauritian cynomolgus macaques and analysis of virus populations. <i>Antiviral Research</i> , 2017, 140, 95-105.	4.1	13
66	The safety profile of favipiravir should not be the first argument to suspend its evaluation in viral hemorrhagic fevers. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008259.	3.0	13
67	A new method for evaluation of the Fisher information matrix for discrete mixed effect models using Monte Carlo sampling and adaptive Gaussian quadrature. <i>Computational Statistics and Data Analysis</i> , 2017, 111, 203-219.	1.2	12
68	Model Averaging in Viral Dynamic Models. <i>AAPS Journal</i> , 2020, 22, 48.	4.4	12
69	Evaluation of the Fisher information matrix in nonlinear mixed effect models using adaptive Gaussian quadrature. <i>Computational Statistics and Data Analysis</i> , 2014, 80, 57-69.	1.2	11
70	Modeling the Effect of DAV132, a Novel Colon-Targeted Adsorbent, on Fecal Concentrations of Moxifloxacin and Gut Microbiota Diversity in Healthy Volunteers. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1045-1054.	4.7	11
71	Influence of the Size of Cohorts in Adaptive Design for Nonlinear Mixed Effects Models: An Evaluation by Simulation for a Pharmacokinetic and Pharmacodynamic Model for a Biomarker in Oncology. <i>Pharmaceutical Research</i> , 2015, 32, 3159-3169.	3.5	10
72	Ribavirin does not potentiate favipiravir antiviral activity against Ebola virus in non-human primates. <i>Antiviral Research</i> , 2020, 177, 104758.	4.1	10

#	ARTICLE	IF	CITATIONS
73	Optimal Design for Informative Protocols in Xenograft Tumor Growth Inhibition Experiments in Mice. AAPS Journal, 2016, 18, 1233-1243.	4.4	9
74	Influence of Covariance Between Random Effects in Design for Nonlinear Mixed-Effect Models with an Illustration in Pediatric Pharmacokinetics. Journal of Biopharmaceutical Statistics, 2014, 24, 471-492.	0.8	7
75	CPT: Pharmacometrics & Systems Pharmacology "Inception, Maturation, and Future Vision. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 649-657.	2.5	6
76	Bayesian Individual Dynamic Predictions with Uncertainty of Longitudinal Biomarkers and Risks of Survival Events in a Joint Modelling Framework: a Comparison Between Stan, Monolix, and NONMEM. AAPS Journal, 2020, 22, 50.	4.4	5
77	Once-daily dosing of saquinavir soft-gel capsules and ritonavir combination in HIV-1-infected patients (IMEA015 study). Antiviral Therapy, 2004, 9, 247-56.	1.0	5
78	Robust designs in longitudinal studies accounting for parameter and model uncertainties " application to count data. Journal of Biopharmaceutical Statistics, 2020, 30, 31-45.	0.8	4
79	Robust designs accounting for model uncertainty in longitudinal studies with binary outcomes. Statistical Methods in Medical Research, 2020, 29, 934-952.	1.5	4
80	Tutorial for \$DESIGN in NONMEM: Clinical Trial Evaluation and Optimization. CPT: Pharmacometrics and Systems Pharmacology, 2021, , .	2.5	4
81	Modeling the bacterial dynamics in the gut microbiota following an antibiotic-induced perturbation. CPT: Pharmacometrics and Systems Pharmacology, 2022, 11, 906-918.	2.5	4
82	Individual Bayesian Information Matrix for Predicting Estimation Error and Shrinkage of Individual Parameters Accounting for Data Below the Limit of Quantification. Pharmaceutical Research, 2017, 34, 2119-2130.	3.5	3
83	Developing Tools to Evaluate Non-linear Mixed Effect Models: 20 Years on the npde Adventure. AAPS Journal, 2021, 23, 75.	4.4	3
84	Finding optimal design in nonlinear mixed effect models using multiplicative algorithms. Computer Methods and Programs in Biomedicine, 2021, 207, 106126.	4.7	3
85	A Colon-Targeted Adsorbent (DAV132) Does Not Affect the Pharmacokinetics of Warfarin or Clonazepam in Healthy Subjects. Clinical Pharmacology in Drug Development, 2021, 10, 908-917.	1.6	2
86	High doses of favipiravir in two men survivors of Ebola virus disease carrying Ebola virus in semen in Guinea. IDCases, 2022, 27, e01412.	0.9	2
87	Comment on Jaki et al., A proposal for a new PhD level curriculum on quantitative methods for drug development. Pharmaceutical Statistics 17 (5):593-606, Sep/Oct 2018, DOI: 10.1002/pst.1873. Pharmaceutical Statistics, 2019, 18, 278-281.	1.3	1
88	Comparison of Various Phase I Combination Therapy Designs in Oncology for Evaluation of Early Tumor Shrinkage Using Simulations. CPT: Pharmacometrics and Systems Pharmacology, 2020, 9, 686-694.	2.5	1
89	Welcome to the statistics and pharmacometrics themed issue. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 273-274.	2.5	1
90	Impact of study design and statistical model in pharmacogenetic studies with gene-treatment interaction. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 340-349.	2.5	1

#	ARTICLE	IF	CITATIONS
91	<i>CPT: Pharmacometrics & Systems Pharmacology</i> 2.0. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019, 8, 195-196.	2.5	0